GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » Capex-to-Revenue

CombiGene AB (OSTO:COMBI) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is CombiGene AB Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

CombiGene AB's Capital Expenditure for the three months ended in Dec. 2024 was kr0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was kr0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


CombiGene AB Capex-to-Revenue Historical Data

The historical data trend for CombiGene AB's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CombiGene AB Capex-to-Revenue Chart

CombiGene AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only - - - 0.02 -

CombiGene AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CombiGene AB's Capex-to-Revenue

For the Biotechnology subindustry, CombiGene AB's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CombiGene AB's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CombiGene AB's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where CombiGene AB's Capex-to-Revenue falls into.


;
;

CombiGene AB Capex-to-Revenue Calculation

CombiGene AB's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.326
=0.00

CombiGene AB's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CombiGene AB  (OSTO:COMBI) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


CombiGene AB Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of CombiGene AB's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CombiGene AB Business Description

Traded in Other Exchanges
N/A
Address
Agavagen 52A, Lidingo, SWE, SE-181 55
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

CombiGene AB Headlines

No Headlines